The increased expression of APE1 in EGFR‐TKI‐resistant cells implicated APE1 in the development of TKI resistance n NSCLC, suggesting that targeting APE1 may represent a strategy for overcoming the acquired resistance of NSCLC cells against TKI treatment33,34. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.